Annual Report 2014
CURES START HERE. That's the theme of this year's report and it succinctly captures the story of our center. Fred Hutch has historically had a reputation as the world leader in curing blood-borne cancers. But this remarkable accomplishment is only part of the story. Our scientists conduct research that relates to a wide spectrum of cancers — and a host of other diseases, too.
In this last year alone, our scientists have made dozens of scientific breakthroughs. Most widely covered in the media has been our work in the area of immunotherapy, which is among the most exciting developments in the search for cancer cures. But as you read this annual report, you can learn more about the myriad discoveries being made by Hutch scientists.
Fred Hutch, however, is not just a research institution. Our scientist-physicians apply research findings every day in the real world. In the last year, over 7,000 patients were treated at Seattle Cancer Care Alliance (SCCA), our affiliated clinical branch where we join forces with Seattle Children's and UW Medicine. At SCCA, we translate our world-class science into patient care. SCCA treats more cancer cases than any other medical center in the region and is the place where patients with rare, complex and advanced cancers gain hope through novel therapies.
In the past year, Fred Hutch has faced a number of challenges, the greatest of which has been reduced funding from our largest supporters, the National Institutes of Health. Your Board of Trustees has embarked on a strategy to diversify our funding sources and ensure our success far into the future. Meanwhile, we have been heartened by the generosity of our donors. In this last fiscal year, Fred Hutch received the largest gift in our history — a $20 million gift from the Bezos family — as well as exceeded all previous records for donations.
In May, the Board accepted the resignation of Fred Hutch's president and director, Dr. Larry Corey, which took effect June 30, the end of our fiscal year. We are grateful for all that Dr. Corey accomplished in his tenure. The Board is conducting an international search for a successor and expects to announce a selection shortly. Meanwhile, we appreciate the leadership of our deputy directors, Dr. Mark Groudine and Dr. Fred Appelbaum, during this transition.
It is an honor to serve as the Chair of the Board of Trustees. My fellow trustees have shown singular dedication to Fred Hutch. In return, we are privileged to associate with extraordinary scientists. We see firsthand how their breakthroughs translate into saving lives. We are grateful to them for their unwavering commitment to lives of science — and to you, our benefactors, for your continued and generous support.
At Fred Hutch, our sights are set on a cancer-free future. This goal drives us to develop tomorrow's breakthroughs today. By supporting Fred Hutch, you can help propel our lifesaving research. Please give now.